top of page
Recent News & Press Releases
Search
Business Wire
Nov 13, 20245 min read
Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association and Announces Appointment of Disarm Therapeutics’ Founders to SAB
November 13, 2024 09:30 AM Eastern Standard Time CINCINNATI--( BUSINESS WIRE )-- Asha Therapeutics  (Asha), a life sciences company...
Business Wire
Mar 31, 20243 min read
Asha Therapeutics Announces the Nomination of a Novel Intra-Molecular Glue Development Candidate ASHA-624 as a Disease Modifying Therapeutic for Amyotrophic Lateral Sclerosis
CINCINNATI--(BUSINESS WIRE)--Asha Therapeutics (Asha) (www.ashatherapeutics.com), a life sciences company designing de novo disease...
Business Wire
Mar 9, 20244 min read
Asha Therapeutics to Present at AD/PDâ„¢ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year
CINCINNATI--(BUSINESS WIRE)--Asha Therapeutics (Asha), (www.ashatherapeutics.com), a life sciences company, is leveraging its...
PR Newswire
Sep 22, 20233 min read
Asha Therapeutics Selected as a BLUE KNIGHTâ„¢ Company by Johnson & Johnson Innovation and BARDA
Asha Therapeutics (Asha), (www.ashatherapeutics.com), a biopharmaceutical company revolutionizing the traditional multi-year drug...
JnJ Innovation
Aug 31, 20234 min read
Inside the Innovation Arena – A Recap of Our BLUE KNIGHT™ QuickPitch: Activating for the Future
August 31, 2023 - Earlier this week, innovation took center stage at the BLUE KNIGHTâ„¢ QuickPitch: Activating for the Future. 10...
Asha TX
Jun 23, 20231 min read
Asha TX to present breakthrough data for ASHA-044 tareting Beta-Catenin in colorectal cancer at NGIO
Asha Therapeutics will be presenting new data at the 6th Annual Next-Gen Immuno-oncology Conference showing robust efficacy of their...
Asha TX
Jun 10, 20232 min read
Targeting mitochondria in ME/CFS and Long Haul COVID with ASHA-091
Asha Therapeutics presented exciting new data for their lead Parkinson's Disease therapeutic ASHA-091 in one of its secondary indications...
Asha TX
Apr 13, 20231 min read
Asha Therapeutics Announces the Presentation of New Data on ASHA-1007, a Novel VHL Recruiter for TPD
See Full Press Release Here Asha Therapeutics presented their novel VHL recruiter technology at Third Annual Ligase Targeting Drug...
Asha TX
Mar 15, 20231 min read
Asha Therapeutics CSO, Dr. Bradlee Heckmann speaking at AD/PD 2023
Asha Therapeutics' scientific co-founder and CSO, Dr. Bradlee Heckmann will be presenting at the international AD/PD 2023 meeting in...
Alan Carregal
Feb 10, 20232 min read
Asha Therapeutics Announces the Appointment of Dr. Craig Blackstone to its Board of Directors
February 10, 2023 Asha Therapeutics is pleased to announce the appointment of Dr. Craig Blackstone as a member of its Board of Directors...
Alan Carregal
Feb 7, 20232 min read
Asha Therapeutics Appoints Kirsten Flowers to its Board of Directors
Asha Therapeutics (Asha), announced today the appointment of Kirsten Flowers to its Board of Directors. Asha’s PRISM™ technology has...
ashaconsultant2
Oct 7, 20222 min read
Dr. Craig Blackstone, M.D., Ph.D., appointed as Chair, Asha Therapeutics’ Scientific Advisory Board
Asha Therapeutics www.ashatherapeutics.com announced today that it has appointed Dr. Craig Blackstone, Chief of the Movement Disorders...
-
Jun 21, 20221 min read
Asha Therapeutics presents at 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference
Sam Shrivastava (Asha CEO) and Dr. Bradlee Heckmann (Asha CSO) present updates on neuro-oncology assets and ASHA-044
-
Jun 21, 20221 min read
ASHA-091 demonstrates efficacy in Parkinson’s Disease
Asha Therapeutics' lead mitochondrial dynamics targeting drug ASHA-091 demonstrates robust efficacy and safety in preclinical murine...
bottom of page